In a study with triple-negative breast cancer cells, the natural cannabinoids CBD (cannabidiol) and THCV (tetrahydrocannabivarin) counteracted the development of resistance to the chemotherapeutic agent doxorubicin.
This drug is usually given in the process of chemotherapy and makes it a significant concern during this period. The study contemplated the function of the potential anticancer effects of cannabinoids: cannabidiol (CBD) and tetrahydrocannabivarin (THCV) in their natural and synthetic form.
In the case of the study of the anticancer potency effects in synthetic CBD and THCV were studied in combination with doxorubicin (DOX) against cells resistant to MDA-MD-231. This treatment significantly increased the cytotoxicity of DOX.
“Transcriptomics and proteomics studies revealed that CBD and THCV, by regulating downward PD-L1, TGF-β, sp1, NLRP3, P38-MAPK and upregulating AMPK, induced apoptosis that led to improved DOX chemo sensitivity against DOX-resistant MDA-MB-231 tumors in BALB/c naked mice. CBD/THCV in combination with DOX significantly inhibited H3k4 methylation and H2K5 acetylation, as evidenced by Western transfers and RT-PCR,” the research says.
It is concluded that CBD and THCV appear to counteract histone modifications and their subsequent effects on DOX, resulting in chemosensitization against MDA-MB-231-resistant cancers.
Full study: https://bit.ly/3l00Ujj
in Costa Rica. 
